Back

Uninterrupted novel anticoagulants as safe alternative of transesophageal echocardiographic screening in patients undergoing ablation for atrial fibrillation

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Drug treatment Antiarrhythmic drugs ESC Premium Access ESC Congress 2017

About the speaker

Photo
Mrs Albina Shapieva

Sana-Herzzentrum Cottbus, Cottbus (Germany)

24 More presentations in this session

Presentation thumbnail
Impact of digoxin use on adverse outcomes in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study in China
Miss S. Wu (Beijing, CN)
Abstract Slides
Presentation thumbnail
Rate-control treatment and clinical outcomes in patients with atrial fibrillation and obstructive lung disease
Doctor S. You (Seoul, KR)
Abstract Slides
Presentation thumbnail
Efficacy of acute intravenous therapy with potassium, magnesium and metoprolol in recent-onset atrial fibrillation
Miss A. Moser (Hamburg, DE)
Abstract
Presentation thumbnail
Postoperative atrial fibrillation in patients with reduced ejection fraction heart failure undergoing cardiac surgery: ranolazine shortens time to conversion when added to amiodarone
Professor J. Skoularigis (Larissa, GR)
Abstract Slides
Presentation thumbnail
INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin
Doctor P. Oliveira Guimaraes (Durham, US)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Drug treatment

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources